Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS

Treatment results of AML in elderly patients are unsatisfactory. We hypothesized that addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy may improve outcome in this population. After establishing a safe dose in a run-in phase of the study in 22 patients, 231 eligible pati...

Full description

Bibliographic Details
Main Authors: Jeroen Janssen, Bob Löwenberg, Markus Manz, Mario Bargetzi, Bart Biemond, Peter von dem Borne, Dimitri Breems, Rolf Brouwer, Yves Chalandon, Dries Deeren, Anna Efthymiou, Bjørn-Tore Gjertsen, Carlos Graux, Michael Gregor, Dominik Heim, Urs Hess, Mels Hoogendoorn, Aurelie Jaspers, Asiong Jie, Mojca Jongen-Lavrencic, Saskia Klein, Marjolein van der Klift, Jürgen Kuball, Danielle van Lammeren-Venema, Marie-Cecile Legdeur, Arjan van de Loosdrecht, Johan Maertens, Marinus van Marwijk Kooy, Ine Moors, Marten Nijziel, Florence van Obbergh, Margriet Oosterveld, Thomas Pabst, Marjolein van der Poel, Harm Sinnige, Olivier Spertini, Wim Terpstra, Lidwine Tick, Walter van der Velden, Marie-Christiane Vekemans, Edo Vellenga, Okke de Weerdt, Peter Westerweel, Georg Stüssi, Yvette van Norden, Gert Ossenkoppele
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
AML
high-risk MDS
tosedostat
clinical trial
aminopeptidase inhibitor
elderly
Online Access:https://www.mdpi.com/2072-6694/13/4/672

Internet

https://www.mdpi.com/2072-6694/13/4/672

Similar Items